肿瘤细胞治疗研究
英文原题：SOHO State of the Art Updates and Next Questions | Novel Immunotherapy Combinations for the Treatment of Indolent B-Cell Lymphoma.
SOHO State of the Art Updates and Next Questions | Novel Immunotherapy Combinations for the Treatment of Indolent B-Cell Lymphoma.
化学免疫治疗（CIT）是晚期惰性非霍奇金淋巴瘤（iNHL）的标准一线治疗。
化学免疫治疗（CIT）是晚期惰性非霍奇金淋巴瘤（iNHL）的标准一线治疗方案。虽然基于来那度胺的免疫治疗仍是复发iNHL的标准治疗，但其一线使用受限，原因在于与CIT相比并无优效性。能够衔接T细胞、将巨噬细胞表型极化为更具抗肿瘤活性的表型，和/或靶向表观遗传通路的药物可能增强免疫治疗。在本综述中，我们总结了已发表和/或正在进行的临床试验的安全性和疗效数据，这些试验研究了基于来那度胺的免疫治疗与T细胞衔接器（包括抗CD3/CD20双特异性抗体）、巨噬细胞靶向药物（包括BTK抑制剂和抗CD47抗体）以及表观遗传修饰剂（包括EZH2抑制剂）的联合应用。我们还总结了靶向CD20以外抗原（包括CD19和CD79b）的药物，以及新型免疫治疗和细胞治疗（包括基于NK细胞的治疗）在iNHL中的活性。iNHL的治疗格局即将发生显著变化。
Chemoimmunotherapy (CIT) is the standard frontline treatment for advanced indolent non-Hodgkin lymphomas (iNHL). While lenalidomide-based immunotherapy remains the standard of care for relapsed iNHL, its frontline use is limited, due to nonsuperiority as compared to CIT. Agents that engage T-cells, polarize macrophage phenotype to a more antitumoral phenotype, and/or to target epigenetic pathways could enhance immunotherapy. We summarize in this review safety plus efficacy data from published and/or ongoing clinical trials investigating the combination of lenalidomide-based immunotherapy with T-cell engagers (including anti-CD3/CD20 bispecific antibodies), macrophage-targeting agents (including BTK inhibitors and anti-CD47 antibodies), and epigenetic modifiers (including EZH2 inhibitors). We also summarize the activity in iNHL of agents targeting antigens other than CD20 (including CD19 and CD79b), and novel immunotherapies and cellular therapies (including NK-cell based treatments). The therapeutic landscape of iNHL is soon to significantly change.
MEMBER ACCOUNT
登录成功会直接打开下一页。
